Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Finalizes Reimbursement For Exact Sciences’ Colorectal Cancer Test

This article was originally published in The Gray Sheet

Executive Summary

The agency affirmed a positive payment rate for Exact Science's Cologuard DNA stool test. The firm says it is beginning to implement its marketing plan targeting docs that more frequently prescribe fecal tests, and patients more broadly on social media.


Related Content

Exact Sciences Colon Cancer Test Gets Quick Results From CMS
Parallel Review Progress: FDA Approves, CMS Assesses Cologuard Cancer Test





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts